This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Randall E. Harris, MD, PhD; Kadambari K. Namboodiri, PhD; William B. Farrar, MD; Sandra M. Solano, MD
The Ohio State University Columbus

Ernst L. Wynder, MD
American Health Foundation New York, NY

JAMA. 1996;275(15):1158-1159.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The article by Dr Stanford and colleagues¹ attracted strong media attention to the issue of estrogen replacement therapy (ERT) and breast cancer risk. Although their epidemiological case-control study found no overall risk increase associated with ERT, the authors did observe "[m]odest increased risk estimates... in thin women who used menopausal hormone therapy." Other investigators also have observed elevations in breast cancer risk associated with ERT in lean postmenopausal women.

Our literature search for 1985 to 1995 identified six published epidemiological investigations^1-6 that provided estimates of breast cancer risk associated with ERT in postmenopausal women and stratified on body mass index (BMI). A meta-analysis of the relative risks (RR) for relatively low BMI is shown in Table 1. The estimates of RR show a narrow range (1.3 to 2.2), and the combined data suggest a 70% increase in breast cancer risk associated with ERT in lean . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?